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Neurogenic inflammation: mechanisms and species
differences
The term ‘neurogenic inflammation’ refers to a series of
proinflammatory responses produced by the stimulation
of peripheral terminals of a subset of primary sensory neu-
rons and the subsequent release of the neuropeptides, cal-
citonin gene-related peptide (CGRP) and the tachykinins,
substance P (SP) and neurokinin A (NKA) [1]. The neu-
rons that produce inflammation comprise a heterogeneous
cell population with A-delta and C fibres, defined as
polymodal nociceptors because they sense thermal, chem-
ical and high-threshold mechanical stimuli. These neurons
express on their plasma membrane a large panel of excita-
tory and inhibitory receptors and channels, and some of
these signalling proteins have been successfully used as
targets for analgesic or anti-inflammatory drugs. Among
the channels expressed on peptidergic primary sensory
neurons, transient receptor potential vanilloid-1 (TRPV1)
[2], activated by the xenobiotic capsaicin, the pungent
ingredient of plants of the genus Capsicum, is of para-
mount importance. Capsaicin produces burning pain by
stimulating TRPV1 and by releasing sensory neuropep-
tides causes neurogenic inflammation. However, high
concentrations/doses of capsaicin have the ability, after an
initial excitatory phase, to desensitise the sensory nerve
terminals, thus reducing the transmission of sensory/pain
signals and abolishing neurogenic inflammation [3, 4].
This specific feature of capsaicin has greatly contributed
to define the role of this subset of sensory nerves in patho-
physiological models of human diseases and has been
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Abstract For more than a century
neurogenic inflammation has been
proposed to have a role in various
human diseases. The present review
will cover the conceptual steps of the
itinerary that has led to the conclu-
sion that neurogenic inflammation is
important in migraine. Of particular
relevance for the object of this article
is the observation that tachykinin-
dependent neurogenic inflammatory
responses are evident in rodents, but
much less pronounced or absent in
other mammal species, including
man, whereas neurogenic vasodilata-
tion, most likely mediated by CGRP,
occurs in most mammalian species
and also in man. Recent evidence
that a CGRP receptor antagonist was
effective in the treatment of migraine
attack supports the hypothesis that
neurogenic vasodilatation is a major
underlying mechanism of migraine.
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used as a therapeutic strategy in certain pain and inflam-
matory conditions [1]. From a large body of evidence
accumulated in the last few decades, the general hypothe-
sis has originated that neurogenic inflammation is the
underlying mechanism in different human diseases,
including migraine and other primary headaches [1].
Neurogenic inflammation occurs mainly at the vascular
levels, where in almost every organ of mammals it compris-
es CGRP-mediated arteriole vasodilatation and tachykinin-
mediated plasma protein extravasation and leukocyte adhe-
sion to the venule endothelium. In extravascular tissues,
marked differences exist according to tissue and species.
Thus, for example, in the airways tachykinins mediate an
epithelium-dependent bronchodilatation in the mouse and
rat, whereas in guinea pigs and man severe bronchocon-
striction is produced [1]. In contrast with the guinea pig, in
the urinary bladder of the rat the dilatation of the bladder
produced by CGRP is absent, while tachykinin-mediated
contraction prevails [1]. More recent evidence obtained with
the advent of specific and high affinity antagonists for
tachykinin and CGRP receptors have clarified that species-
dependent differences in neurogenic inflammation respons-
es exist also at the vascular level. These differences have
markedly influenced the process through which the knowl-
edge of the contribution of sensory nerves and neurogenic
inflammation in migraine has been developed.
Vascular components of neurogenic inflammation
Biological effects produced by tachykinins are mediated
by three different heterotrimeric G-protein coupled recep-
tors, the NK1, NK2 and NK3 receptors. These receptors
are associated with Gq/11 proteins and their stimulation
results in the mobilisation of Ca2+ ions in the cytosol.
Neurogenic plasma protein extravasation occurs at the
level of postcapillary venules where SP and NKA,
released from sensory nerve terminals, stimulate NK1
receptors on endothelial cells, thus increasing Ca2+ mobil-
isation and activating intracellular contractile elements.
The contraction causes the opening of gaps between
endothelial cells, a phenomenon that allows the passage of
macromolecules, including albumin, into the interstitial
space and the formation of inflammatory oedema.
Leukocyte adhesion to the venule endothelium, also medi-
ated by NK1 receptor activation [5], follows and potenti-
ates the early inflammatory responses and is accompanied
by mast cell degranulation and inflammatory mediator
production. Evidence that trigeminal nerve stimulation
results in plasma protein extravasation in the meninges of
rodents suggested that this mechanism could be important
for the clinical manifestation of migraine [6]. The obser-
vation that triptans blocked, presumably at a prejunction-
al site of action, neurogenic plasma extravasation, further
corroborated the hypothesis [7]. The discovery of non-
peptidic, high affinity and selective NK1 receptor antago-
nists allowed the design of clinical studies aimed to veri-
fy whether NK1 receptor blockade could be beneficial in
the migraine attack. However, more than one antagonist
with a good pharmacodynamic and pharmacokinetic pro-
file resulted non-effective in clinical trials [8, 9].
A careful critical analysis of the features of neurogenic
inflammation in man should have cast doubts regarding the
effectiveness of NK1 blockers to ameliorate migraine
headaches. Capsaicin administration to human skin causes
a remarkable erythema and arteriolar vasodilatation [10],
presumably mediated by CGRP release, but there is little or
no evidence that capsaicin causes cutaneous plasma
extravasation. Whereas in man SP and NKA potently con-
tract the bronchi and the urinary bladder, capsaicin does
not. Finally, failure of capsaicin to release SP/NKA from
human sensory nerve terminals in vitro has been reported
[11]. From these findings it may be concluded that if the
release of sensory tachykinins occurs in human tissues, this
would not be sufficient to produce the biological effects
commonly observed in rodents. In contrast, the observa-
tions that capsaicin application to the human skin produces
a neurogenic flare response, most likely mediated by CGRP
[10, 12] and that capsaicin releases CGRP from human tis-
sues in vitro [11, 13] have important implications for our
current understating of migraine mechanism and the treat-
ment of migraine attack. Mechanistic studies in experimen-
tal animals and a recent clinical trial have corroborated the
hypothesis that sensory CGRP and neurogenic inflamma-
tion have a central role in migraine pathogenesis.
Calcitonin-related peptides
In 1982, it was discovered that alternative processing of
RNA transcripts from the calcitonin gene results in the
production of distinct mRNAs encoding a 37-amino acid
neuropeptide, called CGRP [14]. Whereas the calcitonin
mRNA predominates in the thyroid, the specific mRNA
for CGRP is abundant in the nervous system [15]. Sub-
sequently, a human form of CGRP was isolated from thy-
roid tissue of patients with medullary thyroid carcinoma
[16]. CGRP is now known to belong to a family that
includes the more recently discovered peptides adreno-
medullin (AM) and amylin. AM was isolated from human
pheochromocytoma cells in 1993 as a 52-amino acid pep-
tide, which was able to stimulate cAMP production in
platelets [17]. Endothelial and vascular smooth muscle
cells, especially upon stimulation with inflammatory
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cytokines, are among the many cell types that can produce
AM [18]. The amyloid deposits in the pancreas of non-
insulin-dependent diabetics [19] were the source of the
37-amino acid peptide, amylin, or islet amyloid polypep-
tide (IAPP), which shares some structural homology with
CGRP and AM. Amylin is secreted with insulin from pan-
creatic β-cells after meals, and its major physiological
effect is the regulation of glucose metabolism in the oppo-
site manner to insulin with respect to glycogen synthesis
and glucose uptake into muscle [20].
CGRP peptides
The two isoforms of CGRP, α and β, are found in most
species, differ by one and three amino acids, and exhibit
similar functional activities [14, 16]. One of the two
forms, αCGRP, encoded by the calcitonin gene, is the
more abundant and found in discrete areas of the central
and peripheral nervous system. In man, βCGRP, which
differs from αCGRP by three amino acids, is primarily
located within enteric nerves [21] and the pituitary gland
[22]. The nerve growth factor (NGF) is of outmost impor-
tance in influencing plasticity of CGRP because it regu-
lates the growth and maintenance of sensory nerve func-
tion [23]. The half-life of CGRP in the circulation is
~7–10 min in the human plasma [24]. CGRP metabolism
is not regulated by an identified proteolytic pathway and
it is probably broken down via a number of routes.
Efficient cleavage of CGRP into inactive fragments is pro-
duced by mast cell tryptase in the skin [25], and matrix
metalloproteinase II has the ability to metabolise CGRP
and remove its vasodilator activity [26], whereas CGRP is
a poor substrate for neutral endopeptidase, so this path-
way is probably less important as a route for CGRP degra-
dation in peripheral tissues [27].
CGRP and its receptor: a unique story
In the late 1980s, the existence of two receptors was orig-
inally proposed: CGRP1 and CGRP2, with the CGRP1
receptor being the predominant mediator of CGRP effects
in the guinea pig or rat atrium, whereas the CGRP2 recep-
tor activity was identified by the CGRP-induced inhibition
of electrically evoked twitch responses in the rat vas def-
erens [28]. CGRP8–37, a 30-amino acid fragment of CGRP,
behaves as an antagonist and shows a relative selectivity
for the CGRP1 receptor [29]. Rat calcitonin receptor-like
receptor (CL) was cloned in 1993 [30]. The 7 transmem-
brane domains human isoform of rat CL was cloned 2
years later and consists of 461 amino acids with 91 and
56% identity to the rat orphan calcitonin receptor-like
sequence and the human calcitonin receptor, respectively
[31]. Because this receptor did not bind CGRP in the cells
studied, it was considered an orphan receptor. However,
when the cDNA was expressed in human embryonic kid-
ney 293 (HEK293) cells it exhibited specific, high-affinity
binding sites for CGRP and displayed functional proper-
ties, including increase in cAMP production, similar to the
human CGRP1 receptor [32]. However, because CL
expression in COS-7 cells failed to produce a functional
receptor, it was concluded that HEK293 cells must also
possess a factor essential for the production of a function-
al receptor. The puzzle was solved after the discovery of
the receptor activity-modifying protein (RAMP), a single
transmembrane domain protein with 148 amino acids nec-
essarily required to associate with CL to confer receptor
activity [33]. Receptors for CGRP/AM that have been
cloned and characterised so far consist of a seven-trans-
membrane G protein-coupled CL receptor in association
with one of three single membrane-spanning RAMPs.
RAMP1 associated with CL produces a CGRP receptor
(CGRP1) that is antagonised by the CGRP antagonist
CGRP8–37 (Table 1). In particular, it has been shown that
Table 1 Receptors for calcitonin and related peptides
Calcitonin Amylin (AMY) CGRP Adrenomedullin (AM)
Composition CALCR AMY-1: CALCR+RAMP1 CALCRL+RAMP1 AM-1: CALCRL+RAMP2
AMY-2: CALCR+RAMP2 AM-2: CALCRL+RAMP3
AMY-3: CALCR+RAMP3
Transduction pathway Gs/Gq Gs Gs/Gq Gs
Selective agonists Human CT AMY α-CGRP AM
Selective antagonists – – BIBN4096BS (+++) AMn22-52
SB-273779 (+)
Potency Salmon CT≥human Salmon CT≥AMY≥ CGRP>AM≥ AM-1: AM>>CGRP>




the N-terminus of RAMP1 is the key determinant for
CGRP binding, which could be due to the interaction of
calcitonin receptor-like receptor with the RAMP1 N-termi-
nus [34]. RAMP2 association with CL results in the AM
(AM1) receptor that can be antagonised by the weak AM
peptide antagonist AM22–52 and the association of RAMP3





(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, [R-(R*,S*)]), is a
competitive non-peptide potent antagonist at the human
CGRP1 receptor [35]. Its affinity (Ki, 14.4±6.3 pM) for
human CGRP1 receptors in a human neuroblastoma cell line
(SK-N-MC cells) was remarkably high. Other antagonists
with lower affinities are Compound 1, (4-(2-oxo-2,3-dihy-
dro-benzoimidazol-1-yl)-piperidine-1-carboxylic acid [1-
3,5-dibromo-4-hydroxy-benzyl)-2-oxo-2-(4-phenyl-piper-
azin-1-yl)-ethyl]-amide) and SB-273779 [N-methyl-N-(2-
methylphenyl)-3-nitro-4-(2-thiazolylsulfinyl)-nitroben-
zanilide]. Compound 1 showed a pKi of 7.8 in binding
experiments on SK-N-MC as compared to 8.9 of CGRP8-37
[36]. SB-273779 is selective for the CGRP receptor but is
less potent than BIBN4096BS, with a Ki value of 310±40
nM on SK-N-MC cells, and it also exhibited low potency in
rat and porcine lungs [37].
Prejunctional modulation of CGRP release
The release of sensory neuropeptides, including CGRP,
undergoes a fine tuning by a series of mediators and
agents that act at prejunctional receptors/channels on sen-
sory nerve terminals. Evidence indicates a range of G pro-
tein-coupled receptors that include those for bradykinin,
prostanoids, opioids, 5-hydroxytryptamine (5-HT1 recep-
tor), histamine (H3 receptor), neuropeptide Y, somato-
statin, vasoactive intestinal polypeptide, purines and
galanin. Among the channels the TRPV1 is the best
known and it can be activated by noxious temperatures,
low extracellular pH and a series of lipid derivatives [2,
38–41]. TRPV1 activity can be regulated by the stimula-
tion of certain G protein coupled receptors (bradykinin
and prostaglandins) or tyrosine kinase receptor (NGF)
[42, 43]. Other pathophysiologically relevant agents may
also regulate TRPV1. The recent observation that ethanol
stimulates TRPV1 channels and releases CGRP, by lower-
ing the threshold temperature for channel activation [44],
suggests that the ability of alcoholic beverages to trigger
the migraine attack may be due to this neurogenic inflam-
matory mechanism. The presence of excitatory CGRP
receptors on sensory neurons, within the dorsal root gan-
glia, which may act as stimulatory autoreceptors, has been
reported recently [45]. Inhibition of CGRP release by α2-
adrenoceptors, located presynaptically on sensory neurons
[46], and the ability of CGRP to inhibit the release of nor-
epinephrine from sympathetic nerves [47] in the rat
mesentery circulation, suggest that reciprocal interactions
can occur between the noradrenergic constrictor system
and the sensory (vasodilatatory) system, and are indica-
tive of an important role for CGRP in the regulation of
peripheral blood flow.
Arterial relaxation by CGRP
The vascular effects of CGRP appear most pronounced in
the microvasculature. CGRP is one of the most potent
vasodilator substances identified to date in the microcircu-
lation, with a potency ~10-fold greater than the
prostaglandins and 2–3 orders of magnitude greater than
other classic vasodilators, including acetylcholine, adeno-
sine, 5-HT and SP. The role of CGRP in the regulation of
vascular tone in small vessels is underlined by the observa-
tion that CGRP-containing nerves can pass into the vascu-
lar smooth muscle layer in smaller arteries. CGRP released
at these sites can have profound effects on arteriolar dilata-
tion and on the microvasculature. Although CGRP-contain-
ing nerves also innervate venous tissues, its activity on this
type of vessels has been less investigated. Current evidence
indicates that administration of exogenous CGRP or the
release of endogenous CGRP produces an NO- and
endothelium-independent relaxation that correlates closely
with a rise in intracellular cAMP, activation of protein
kinase A (PKA), and activation of K+ channels (Fig. 1). The
involvement of ATP-sensitive potassium channels [48] in
the vasodilator mechanism of CGRP has been suggested
and subsequently extended to channels sensitive to gliben-
clamide or charybdotoxin (large-conductance Ca2+-activat-
ed K+ channels) in rat pial arterioles [49].
Exceptions to endothelium-independent relaxation to
CGRP occur only in a few tissues, including the rat aorta,
where the relaxation to CGRP depends on the presence of
an intact endothelium and is attenuated by inhibitors of
NO synthase, implying an NO-dependent mechanism [12,
50]. In human internal mammary artery [51] and rat pul-
monary artery [52], a similar endothelium-dependent
mechanism of relaxation has also been seen. Evidence that
CGRP activates phospholipase C in HEK293 cells, lead-
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ing to an increase in intracellular Ca2+ via inositol trispho-
sphate (IP3) [53] suggests that this alternative intracellular
pathway may be responsible for the CGRP-induced
release of NO (Fig. 1). Other peptides of the CGRP fami-
ly may also produce vascular relaxation. There is evidence
that AM acts to relax porcine coronary artery precon-
stricted with U46619 [54]. The vasodilator effects of
amylin appear to be mediated by the CGRP1 receptor as
they are blocked by CGRP8–37.
Migraine and neurogenic inflammation
Our current comprehension of the migraine mechanism is
still incomplete. However, it is possible that genetic abnor-
malities initiate the alteration of the response threshold to
migraine-specific triggers in the brain [55]. Studies using
positron emission tomography have shown increased
blood flow (an index of neuronal activity) during sponta-
neous migraine attacks in the cerebral hemispheres (cingu-
late, auditory and visual suppression areas) and suggest
that the process driving the migraine attack and the area
susceptible to the migraine triggers may be located in the
brain stem [56]. Neural activation eventually results in the
dilatation of cranial blood vessels including carotid arteri-
ovenous anastomoses [57]. There is also evidence in
experimental animals that the migraine aura, rather than
from an ischaemic phenomenon, derives from an initial
neuronal dysfunction and is probably the clinical manifes-
tation of a cortical spreading depression [58, 59]. A reflex
painful vasodilatation of the cranial blood vessels follows
the cerebral oligaemia, and probably derives from activa-
tion of the trigeminal perivascular innervation [55, 57].
Stimulation of trigeminal ganglia/sensory nerves is
regarded as a necessary step for the process that produces
pain and associated symptoms of the migraine attack.
Trigeminal neurons may release neuropeptides and cause
tachykinin-dependent plasma extravasation in cranial tis-
sues, including the meninges and CGRP-dependent arter-
ial vasodilatation. The hypothesis that neurogenic,
tachykinin-mediated plasma protein extravasation could
be the underlying mechanism of the migraine attack [6]
gained support from the findings that specific antimi-
graine drugs, including sumatriptan, are able to suppress
plasma extravasation produced by antidromic stimulation
of trigeminal nerve terminals in the rodent meninges [7].
As mentioned before, this response is entirely mediated by
tachykinin NK1 receptors localised on postcapillary
endothelial cells. Thus, it was proposed that NK1 receptor
antagonists could be beneficial in migraine treatment.
However, various clinical trials showed that different NK1
receptor antagonists, including RPR100893 [9],
GR205171 [60] or lanepitant [8], were not effective for
Fig. 1 The drawing depicts the
mechanisms by which CGRP is
released from the terminal of
TRPV1-expressing sensory neurons
and produces arterial vasodilatation
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the acute treatment of the migraine attack or as pre-emp-
tive treatment of migraine [61]. Although the failure could
be due to a variety of pharmacokinetic or other reasons,
unrelated to the role of neurogenic plasma extravasation
in migraine pathogenesis, it is also possible that
tachykinin release, activation of NK1 receptors and their
action in neurogenic inflammation do not play any role in
this disease.
In contrast, in recent years the hypothesis that the release
of CGRP, which dilates cranial blood vessels and stimulates
sensory nerve transmission, may have a key role in migraine
mechanism, has obtained much attention and experimental
support [62]. Trigeminal nuclei as well as non-myelinated
trigeminal sensory nerve fibres express an abundant CGRP-
like immunoreactivity and cerebral blood vessels are inner-
vated by sensory nerves that store several neuropeptides
amongst which CGRP is the most abundant [63]. A Ca2+-
dependent and capsaicin-sensitive release of CGRP, but not
SP, has been documented from human tissues containing
non-trigeminal [13] or trigeminal [11] sensory nerve end-
ings. Furthermore, plasma concentrations of CGRP, but not
of SP, were elevated during the headache phase of migraine
[64] and cluster headache [65]. There is evidence that intra-
venous infusion of CGRP produces a migraine-like
headache [66], and intravenous infusion of nitric oxide pro-
duces a migraine-like headache with an associated increase
in plasma CGRP levels [67]. In migraine patients baseline
CGRP levels were considerably higher, and the changes in
plasma CGRP levels during migraine attacks were signifi-
cantly correlated with the headache intensity [67].
Action of drugs effective on neurogenic vasodilatation
Ergotamine and triptans have been proposed to abort
migraine attacks by diverse mechanisms, including con-
striction of dilated cranial blood vessels and carotid arte-
riovenous anastomoses [68], reduction of CGRP release
from perivascular trigeminal nerve endings, and inhibition
of nociceptive transmission on peripheral and central end-
ings of trigeminal sensory nerves [55]. Similarly to
rodents, human trigeminal ganglia/sensory nerves express
abundant 5-HT1B/1D receptors [69], thus strengthening the
evidence in favour of the presynaptic inhibitory effects of
triptans [62]. This effect of triptans results from the stim-
ulation of the heterotrimeric G protein-coupled 5-HT1B/1D
receptor that, by inhibiting adenylyl cyclase and cyclic
adenosine monophosphate cytosol levels, reduces neural
activity, including the neuropeptide release. The principle
of inhibiting neuropeptide release from sensory nerve
endings by reducing neuronal functioning represents the
basis of the antimigraine action of the agonist of the
inhibitory adenosine A1 receptor, GR79236 (N-[(2-
methylphenyl)methyl]adenosine (metrifudil), 2-(pheny-
lamino) adenosine). This compound, stimulating A1
receptors, inhibits neurogenic vasodilatation in rats [70],
trigeminal nociception and CGRP release in cats [71], and
trigeminal nociception in humans [72]. Pilot clinical stud-
ies have reported that GR79236 has antimigraine action,
probably due to an inhibitory effect on nociceptive
trigeminal neurons [70]. Despite these encouraging
results, further studies are required to fully establish the
efficacy and safety of adenosine A1 receptor agonists in
migraine.
The adverse effects of triptans and the limitation of
their use in patients with cardiovascular diseases derive
from the ability of this type of drug to maintain the same
vasoconstrictor activity. Selective agonists of the 5-HT1D
receptor, such as PNU-109291 [(s)-3,4-dihydro-1-ethyl]-
N-methyl-1H-2-benzopyran-6-carboximide) [73] or 5-
HT1F receptors such as LY334370 (4-fluoro-N-[3-(1-
methyl-4-piperidinyl)-1H-indol-5-yl]-benzamide) [74]
have been developed with the idea that they should exert
an antimigraine effect by a prejunctional inhibition of
neural activity, and should be devoid of any vascular con-
strictor action. However, PNU-142633 proved to be inef-
fective in the acute treatment of migraine [75] and
LY334370 did show efficacy when used in doses which
may interact with 5-HT1B receptors [74, 76]. Thus, fur-
ther investigation is required to establish whether non-
vasoconstrictor triptans or other compounds acting at pre-
junctional levels of terminals of primary sensory neurons
are useful in the treatment of migraine and related
headaches.
CGRP antagonists in migraine
The alternative approach to treat the migraine attack, by
limiting neurogenic inflammatory vasodilatation, consists
in the blockade of CGRP receptor by selective antago-
nists. The first peptide CGRP receptor antagonist,
CGRP8–37, proved ineffective in migraine treatment [77].
However, its low potency and very short half-life [29] pre-
cluded any firm conclusion on the role of CGRP, its recep-
tor and neurogenic vasodilatation in migraine mechanism.
The discovery of the peptoid BIBN4096BS, an antagonist
characterised by an exceedingly high affinity for the
human CGRP receptor [35], offered evidence in experi-
mental animals that indicated that this drug is a suitable
tool to prove the concept that CGRP exerts a pivotal role
in the migraine pathogenesis. BIBN4096BS was found to
reduce the vasodilatation induced by trigeminal stimula-
tion in marmosets [78], the vasodilator responses induced
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by capsaicin in porcine carotid, including carotid arteri-
ovenous anastomotic dilatation, and CGRP-induced
porcine carotid vasodilatation and arterial-jugular venous
oxygen saturation difference [79]. Thus, BIBN4096BS
could produce, at a postjunctional level (by CGRP recep-
tor blockade), effects similar to those that triptans cause
by reducing CGRP release, and that result in inhibition of
CGRP receptor signalling. Indeed, triptans inhibit trigem-
inal CGRP release in animal experimental models [55,
63], and clinical data show that sumatriptan normalised
the elevated CGRP levels with alleviation of migraine
[55] and cluster headache attack [65]. These findings have
suggested that BIBN4096BS could be developed as an
effective antimigraine drug.
A recent clinical trial has shown that BIBN4096BS is
effective in the acute treatment of migraine without sig-
nificant side effects or intrinsic vasoconstrictor effects
[80]. The CGRP receptor antagonist at a dose of 2.5 mg
was effective in the treatment of the migraine attack with
a response rate of 66% as compared with 27% for place-
bo. BIBN4096BS also showed significant superiority over
placebo in reducing the pain at 2 h and improving the nau-
sea, photophobia, phonophobia, functional capacity and
the time to meaningful relief [80]. Side effects were 25%
with BIBN4096BS and 12% with placebo. The most fre-
quent side effect was paraesthesia and no serious adverse
effect was recorded. Intra- and extracranial vessels and
systemic haemodynamics have been studied in man fol-
lowing BIBN4096BS administration. BIBN4096BS had
no influence on global or regional cerebral blood flow and
did not show any effect on systemic haemodynamics and
adverse events were minor [81]. Thus, CGRP-receptor
blockade does not seem to affect cerebral or systemic cir-
culation in humans. From this finding it is possible to
hypothesise that circulating CGRP in basal condition does
exert a tonic vasodilatatory activity and the use of
BIBN4096BS or other CGRP receptor antagonists should
be without risk of cerebral or systemic vasospasm.
Conclusions
Growing evidence indicates inhibition of CGRP activity
as a major avenue in the treatment of the migraine attack.
Inhibition of neural activity that produces neuropeptide
release from peripheral and central endings of peptidergic
trigeminal neurons has been proposed as one of the key
antimigraine actions of triptans. However, because these
drugs reduce both tachykinin and CGRP release, the iden-
tity of the neuropeptide principally involved in migraine
pathogenesis remained obscure. The uncertainty regarding
the role of one specific neuropeptide mirrors the doubt
regarding the component of neurogenic inflammation
(plasma extravasation vs. arterial vasodilatation) con-
tributing most to migraine pathogenesis. More recent clin-
ical findings reporting the failure of NK1 receptor antag-
onists and the success of one CGRP receptor antagonist
have indicated a major role for CGRP and neurogenic
vasodilatation in migraine mechanism. However, waiting
for further clinical confirmation of the antimigraine activ-
ity of BIBN4096BS or additional CGRP receptor antago-
nists, several questions remain open, and among them,
two are of importance for further development of novel
antimigraine therapeutics. Although the possible target of
BIBN4096BS is a CGRP receptor expressed on the plas-
ma membrane of vascular smooth muscle of cranial arter-
ies, the precise location (neural vs. vascular) of the CGRP
receptors that mediate pain and other symptoms of the
migraine attack are unknown. The second point of uncer-
tainty deals with the safety profile. Further investigation
is, in fact, required to establish whether or not blockade of
CGRP receptor is devoid of any possible vasoconstrictor
activity in clinical conditions in which the sensory nerve
terminal is activated and CGRP released.
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